NEW YORK, Sept. 24 /PRNewswire/ -- Stephen Simes, chief executive officer of BioSante Pharmaceuticals, Inc. (AMEX:BPA) (http://www.biosantepharma.com/) will be featured in an exclusive interview...
BioSante Pharmaceuticals, Inc. (AMEX:BPA) today reported its June 30, 2007 cash balance and its financial results for the second quarter and six months ended June 30, 2007...
BioSante Pharmaceuticals (AMEX: BPA) today announced that BioSante management will present a corporate overview and update at upcoming conferences. The conferences are:...
BioSante Pharmaceuticals, Inc. (Amex: BPA) today announced positive results of the use of BioSante?s calcium phosphate nanotechnology (CaP) as a potential wrinkle filler in...
BioSante Pharmaceuticals, Inc. (Amex: BPA) today announced new positive results demonstrating that?its calcium phosphate (CaP) nanoparticle-based vaccine adjuvant, BioVant?...
NEW YORK, July 10 /PRNewswire/ -- On June 19, Stephen Simes, CEO of Biosante Pharmaceuticals, Inc. (AMEX:BPA) (http://www.biosantepharma.com/ ) updated the investment community in an all-new...
BioSante Pharmaceuticals, Inc. (AMEX:BPA) today announced that the company has been added to the Russell Microcap Index. Stephen M. Simes, president and CEO of BioSante...
BioSante Pharmaceuticals, Inc. (AMEX: BPA) today announced that it and Pantarhei Bioscience B.V., a Netherlands-based pharmaceutical company have initiated a Phase II human...
BioSante Pharmaceuticals, Inc. (AMEX: BPA) today announced that it has completed its previously announced $18.3 million private placement of shares of its common stock and...
FAIRFIELD, N.J., June 13 /PRNewswire-FirstCall/ -- Bradley Pharmaceuticals, Inc. (NYSE:BDY) today announced the launch of Elestrin(TM) (estradiol gel 0.06%) by the Company's Kenwood Therapeutics...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관